Y-Intercept (HK)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Y-Intercept (HK)’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-5,560	Closed	-$2.99M	–	1890
2026 Q2	$2.99M	Buy	+5,560	New	+$2.85M	0.06%	477
2025 Q3	–	Sell	-1,415	Closed	-$428K	–	1846
2025 Q2	$428K	Buy	+1,415	New	+$422K	0.01%	1253
2024 Q4	–	Sell	-1,736	Closed	-$368K	–	1468
2024 Q3	$368K	Buy	+1,736	New	+$444K	0.02%	922
2024 Q1	–	Sell	-1,551	Closed	-$359K	–	1607
2023 Q4	$359K	Buy	+1,551	New	+$271K	0.03%	755
2023 Q1	–	Sell	-871	Closed	-$253K	–	1393
2022 Q4	$253K	Buy	+871	New	+$85.2K	0.04%	732

Other funds holding MDGL

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return

Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Y-Intercept (HK)'s MDGL Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 5,560 shares — an estimated $2.99M sold.

Y-Intercept (HK) first reported a position in MDGL in Q4 2022 and held it in 5 quarters. The position peaked at $2.99M in Q2 2026. 57 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Y-Intercept (HK) reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 5,560 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $2.99M.
Y-Intercept (HK) first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 5 quarters.
Y-Intercept (HK)'s Madrigal Pharmaceuticals position peaked at $2.99M in Q2 2026.
57 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.